Decreasing the risk of UTI in Type 2 Diabetes Mellitus patients on SGLT2 inhibitors

A common diabetes drug is flooding patients’ urine with sugar, and that sugar is feeding bacteria that cause painful urinary tract infections. Researchers want to find out exactly which microbes are taking advantage of this sugary environment. The problem is straightforward: SGLT2 inhibitors lower blood glucose by dumping excess sugar into urine, but that same sugar-rich urine creates a breeding ground for infection. Doctors know the risk exists, but they don’t know which specific microorganisms are responsible, or whether patients on these drugs need different screening or treatment than other diabetes patients. This study will compare urine samples from 15 patients on SGLT2 inhibitors with 15 patients on other diabetes drugs, culturing the microbes and measuring glucose levels and inflammation markers. If the research succeeds, it could change how doctors monitor and treat UTIs in the roughly 5 million UK patients with type 2 diabetes. Instead of prescribing broad-spectrum antibiotics, clinicians might screen for specific pathogens and tailor treatment accordingly. This could reduce antibiotic resistance, shorten infection duration, and prevent recurrent UTIs that otherwise degrade quality of life and strain primary care services.